1455091-10-7

Basic information

• Product Name: FG-4592 interMediate
• Synonyms: FG-4592 interMediate;4-Hydroxy-7-phenoxy-3-isoquinolinecarboxylic acid methyl ester;methyl 4-hydroxy-7-phenoxyisoquinoline-3-carboxylate;3-Isoquinolinecarboxylic acid, 4-hydroxy-7-phenoxy-, methyl ester;FG4592 intermediates;ethyl 4-hydroxy-7-phenoxyisoquinoline-3-carboxylate
• CAS NO: 1455091-10-7
• Molecular Formula: C₁₇H₁₃NO₄
• Molecular Weight: 298.77
• EINECS: -0
• Product Categories: Intermediate;API
• Mol File: 1455091-10-7.mol

Chemical Properties

• Boiling Point: 534.7±45.0 °C(Predicted)
• Appearance: /
• Density: 1.320±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 5.80±0.50(Predicted)
• CAS DataBase Reference: FG-4592 interMediate(CAS DataBase Reference)
• NIST Chemistry Reference: FG-4592 interMediate(1455091-10-7)
• EPA Substance Registry System: FG-4592 interMediate(1455091-10-7)

Safety Data

• Hazardous Substances Data: 1455091-10-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
FG-4592 intermediate is used as a key intermediate in the synthesis of H948180, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor. FG-4592 interMediate is utilized for increasing white blood cell levels in the blood and promoting the production of hematopoietic progenitor cells in the bone marrow. By targeting HIF prolyl hydroxylase, H948180 can potentially improve the treatment of conditions related to low white blood cell counts and enhance the body's response to hypoxia.
Additionally, the development of H948180 and its derivatives may lead to the discovery of new therapeutic agents for various diseases and conditions, further expanding the applications of FG-4592 intermediate in the pharmaceutical industry.

Upstream product

• 1455091-04-9 2-(chloromethyl)-4-phenoxybenzoic acid methyl ester 
• 2645-02-5 methyl tosylglycinate 
• 64169-34-2 5-bromophthalide 
• 1455091-06-1 2-{[(methoxycarbonylmethyl)(toluene-4-sulfonyl)amino]methyl}-4-phenoxybenzoic acid methyl ester 
• 99548-55-7 4-bromo-2-methyl-benzoic acid methyl ester 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 57830-14-5 5-phenoxy-3H-isobenzofuran-1-one 
• 108-95-2 phenol 

Downstream Products

• 1455094-69-5 3-[(4-hydroxy-7-phenoxyisoquinoline-3-carbonyl)amino]-2,2-dimethylpropionic acid ethyl ester 
• 1421312-34-6 4-hydroxy-1-methyl-7-phenoxyisoquinolinyl-3-carboxylic acid methyl ester 
• 1455089-22-1 3-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]propionic acid 
• 1455087-02-1 2-(S)-amino-3-[(4-hydroxy-7-phenoxyisoquinoline-3-carbonyl)amino]propionic acid 
• 1455094-16-2 1-(5-fluoropyridin-3-yl)-4-hydroxy-7-phenoxyisoquinoline-3-carboxylic acid methyl ester 
• 1455089-85-6 3-{[1-(5-fluoropyridin-3-yl)-4-hydroxy-7-phenoxyisoquinoline-3-carbonyl]amino}-2,2-dimethylpropionic acid 
• 1455091-21-0 1-bromo-4-hydroxy-7-phenoxyisoquinoline-3-carboxylic acid methyl ester 
• 1455094-35-5 4-hydroxy-7-phenoxy-1-phenylisoquinoline-3-carboxylic acid methyl ester 
• 1455090-01-3 3-[(4-hydroxy-7-phenoxy-1-phenylisoquinoline-3-carbonyl)amino]-2,2-dimethylpropionic acid 
• 1455090-03-5 3-[(4-hydroxy-7-phenoxy-1-phenylisoquinoline-3-carbonyl)amino]propionic acid 
• 1455094-37-7 4-hydroxy-7-phenoxy-1-(trifluoromethyl)isoquinoline-3-carboxylic acid methyl ester 
• 1455090-05-7 3-[(4-hydroxy-7-phenoxy-1-(trifluoromethyl)isoquinoline-3-carbonyl)amino]propionic acid 
• 1455090-10-4 5-{[1-(5-fluoropyridin-3-yl)-4-hydroxy-7-phenoxyisoquinoline-3-carbonyl]amino}pentanoic acid 
• 1455094-71-9 3-[(4-hydroxy-2-oxy-7-phenoxyisoquinoline-3-carbonyl)amino]-2,2-dimethylpropionic acid ethyl ester 

Relevant articles and documents

Preparation method of isoquinoline derivative

Disclosed is a preparation method of an isoquinoline derivative. A preparation method of a compound represented by a general formula II, i.e., 4-hydroxy-1-methyl-7-phenoxy isoquinoline-3-formate, is provided, wherein substituent definitions are as defined in the specification. The preparation method comprises the following steps of: under an acidic condition, dissolving a compound shown as a structural formula III in dimethyl sulfoxide, catalyzing by a ferrous ion (Fe) catalyst, and oxidizing by H2O2 to obtain the 4-hydroxy-1-methyl- 7-phenoxy isoquinoline-3-formate shown as the structuralformula II. By using the method, the production efficiency can be greatly improved, the production cost is reduced, the product purity can be ensured, and the method is suitable for industrial mass production.

Isoquinolone compound and application thereof

The invention relates to an isoquinolone compound and application thereof. The invention in particular relates to an isoquinolone compound used as a HIF prolyl hydroxylase inhibitor (HIF-PHI) and a pharmaceutical composition thereof. Moreover, the present invention provides the application of the isoquinolinone compound or the pharmaceutical composition thereof in the preparation of a medicament for preventing or treating HIF-associated or HIF-mediated diseases as anemia or ischemia, local ischemia or hypoxia.

A substituted heteroaryl compounds and compositions containing such compounds and use thereof (by machine translation)

The present invention provides a substituted heteroaryl compounds and compositions containing such compounds and its use, the invention discloses a formula (I) indicated by the heteroaryl compound, or its crystalline form, a pharmaceutically acceptable salt, prodrug, stereoisomer, hydrate or compound solvent. The invention of monocyclic the base states compounds and compositions containing such compounds may be used to modulate hypoxia inducible factor (HIF) and/or endogenous erythropoietin (EPO), but also has good pharmacokinetic parameter characteristic, can improve the compound in animal drug concentration, in order to improve the effect of drugs and safety. (by machine translation)

PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS

The present invention relates to methods for making isoquinoline compounds and the intermediate compounds achieved thereby. Such compounds can be used to prepare compounds and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).

4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS

The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.